According to ZERO Prostate Cancer, Novartis has committed $7.5 million to the initiative.

Traditional approaches to HCP segmentation are no longer sufficient. The challenge now is to maintain personalization at ...

The campaign is based on the results of a survey that reveals the experiences of patients and caregivers in their communities ...

Under terms of the deal, Stoke will spearhead global development of zorevunersen, while Biogen will receive exclusive rights ...